Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lundbeck, Takeda deal

Takeda and LUN will co-develop and co-commercialize two of LUN's bisarylsulphanylamines in the U.S.

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE